Does mass spectrometric breath analysis detect *Pseudomonas aeruginosa* in cystic fibrosis?

To the Editor:

*Pseudomonas aeruginosa* associated with increased morbidity and mortality in cystic fibrosis (CF) can be eradicated if detected early; however, prompt detection is problematic in children and non-expectorating adults as oropharyngeal cultures lack sensitivity [1]. We previously reported that 20% of children with negative oropharyngeal cultures isolated *P. aeruginosa* on bronchoalveolar lavage [2], but this invasive technique cannot be performed frequently. Hence, there is an urgent need for a noninvasive screening test for lower airways infection in CF; therefore, we propose that exhaled volatile organic compounds (VOC) may be useful biomarkers.

Over 250 VOC have been detected in exhaled breath using mass spectrometry. *P. aeruginosa* has a characteristic odour related to VOC, such as 2-aminoacetophenone (2-AA) [3]; 2-AA, hydrogen cyanide (HCN) and other compounds have been detected in the exhaled breath of *P. aeruginosa*-infected CF patients [4]. Selected ion-flow tube mass spectrometry (SIFT-MS) allows simultaneous quantification of multiple VOC without costly and time consuming pre-concentration steps [5]. Herein, we report the most comprehensive analysis to date of exhaled VOC in CF patients. We hypothesised that differences in VOC profile can distinguish CF patients with and without chronic *P. aeruginosa* infection.

Following informed consent, adults with CF were recruited from two groups: those with chronic *P. aeruginosa* infection and those without *P. aeruginosa* infection based on the Leeds criteria [6].

Breath sampling and analytical procedures were conducted using a validated method [7]. Following ≥4 h of fasting, subjects provided single exhalations from total lung capacity into double-thickness (2×25 μm) single-use, 2 L Nalophan bags (BOC Ltd, Guildford, UK) pre-flushed with synthetic air. Subjects inhaled fully through the nose (as close to total lung capacity as possible) and exhaled slowly from the mouth directly into the sampling bag. All samples were analysed within 2 h of collection by a Profile 3 SIFT-MS instrument (Instrument Science, Crewe, UK) using full scan and multiple ion monitoring modes as previously described (figure 1a) [7].

Statistical analyses were performed using SPSS Statistics 21.0 (IBM, Armonk, NY, USA) and Prism 6.0 (GraphPad, La Jolla, CA, USA). VOC were incorporated into a binary logistic regression model to discriminate between CF patients with and without *P. aeruginosa* infection. Accuracy of the diagnostic models was assessed using the area under the curve (AUC) of the receiver operating characteristics (ROC) curves. The null hypothesis was rejected at p<0.05.

In the CF patients without *P. aeruginosa* infection (n=29), the median (interquartile range (IQR)) number of culture samples negative for *P. aeruginosa* growth over the preceding 12 months was 8 (5–11). For the CF patients with *P. aeruginosa* infection (n=44) the median (IQR) number of cultures samples was 9 (7–17).

Categorised by most recent culture, 14 (31.8%) had non-mucoid strains, six (13.6%) had mucoid strains and 24 (54.5%) had both phenotypes. CF patients with and without *P. aeruginosa* infection were matched for age, sex, body mass index, CF transmembrane conductance regulator genotype, pancreatic insufficiency, IgE, IgE specific to *Aspergillus fumigatus*, rates of CF-related diabetes and liver disease, and percentage of water levels in exhaled breath. Forced expiratory volume in 1 s (FEV1) was lower in CF patients with *P. aeruginosa* infection (median (IQR) 45 (28.3–61.8) versus 57 (46.0–74.5), p<0.05).

Linear regression analysis showed that any correlations of VOC with FEV1 were weak (e.g. propanol: $r^2=0.066$, dimethyl disulfide (DMDS): $r^2=0.097$), and thus contributed little to any *P. aeruginosa*-related observations.

Of the 12 VOC, significant differences between the CF patients with and without *P. aeruginosa* infection were seen in three VOC (figure 1b). DMDS (p<0.05) and 2-AA were higher (p<0.01) in the CF patients with *P. aeruginosa* infection and butanol was lower (p<0.01). ROC constructed using binary regression of these three VOC resulted in an AUC of 0.774 (95% CI 0.667–0.882) with a sensitivity and specificity of 0.828 and 0.649, respectively. However, using all 12 VOC improved the discrimination of CF patients with
and without P. aeruginosa infection with an AUC of 0.842 (95% CI 0.753–0.930), sensitivity of 0.828 and specificity of 0.705 (figure 1c and d).

The feasibility of using metabolomics for respiratory diagnosis has previously been demonstrated using nuclear magnetic resonance (NMR) spectroscopy of exhaled breath condensate (EBC) to distinguish between asthmatics and healthy controls [8], subjects with CF and primary ciliary dyskinesia [9], and patients with stable and unstable CF [10]. Here, we demonstrate proof-of-concept that a VOC signature is present in exhaled breath (that, unlike NMR spectroscopy of EBC, has potential for real-time analysis), which differentiates groups of CF patients with and without chronic P. aeruginosa infection. Any individual VOC discriminated relatively poorly, even those in which significant group differences were detected; however, by combining VOC signals, high levels of sensitivity and specificity could be achieved. To our knowledge, it is the most comprehensive breath profiling study in CF patients to date. Whilst encouraging, with greater sensitivity than clinically utilised oropharyngeal cultures [1], this compares unfavourably to, for example, [13C] urea breath test for Helicobacter pylori in children (sensitivity 93.8% and specificity 99.1%) [11]. Adding other VOC to this “P. aeruginosa fingerprint” might increase discriminatory capacity to a clinically applicable standard, particularly as improved SIFT-MS sensitivity will allow for detection in
the ppt range [12]. Combining SIFT-MS with highly sensitive chemical sensor arrays (electronic noses) is another option that could enhance accuracy, although this technology also has limitations that would need to be overcome before clinical use [13].

The three markers which demonstrated group differences (2-AA, DMDS and butanol) have all been reported previously as being associated with *P. aeruginosa* infection [14]. However, missing from the group was HCN, which has previously been considered to have biomarker potential. Raised HCN levels have been previously reported in *P. aeruginosa*-infected sputum using a cyanide sensitive electrode [15], and other groups in vitro above bacterial cultures of *P. aeruginosa* with mass spectrometry. In one exhaled breath study, HCN differentiated between CF children with and without *P. aeruginosa* infection [16]. However, in another study [17] and in our cohort no difference was observed, despite our detected levels being similar to those reported in the literature [16, 17]. HCN production varies with *P. aeruginosa* phenotype and genotype [16], which may account for the discrepancy in findings. Furthermore, a recent study suggests that the oral cavity is the main contributor to mouth exhaled HCN [18]. As oral bacterial contamination in adult subjects may be greater than in children [16], nasally exhaled HCN is proposed to be a more accurate biomarker in adults [17]. However, given the almost universal presence of sinus disease in CF adults, and common isolation of *P. aeruginosa* from sinus lavage (in up to 73% of patients [19]), this approach to exhaled breath sampling may not be fully representative of the lower airways; bacterial strains in one study were concordant between upper and lower airways in fewer than 50% of cases [19].

We were interested to note when combining VOC into a diagnostic prediction model that accuracy was improved when all 12 VOC were incorporated, as opposed to using only the three discriminatory VOC. This suggests that other individual VOC are underpowered because of the large coefficient of variation with some compounds, but still contribute to the sensitivity of the binary regression model. Further prospective study is required to elucidate influence of each individual VOC that did not reach statistical significance.

This cross-sectional study has some limitations. Although subjects fasted to reduce the potential influence of oral contamination on VOC concentration, it was not possible to stratify patients by concurrent medications (other than inhaled antibiotics) due to the relatively small sample size and the vast number of drug/dose combinations. It is possible that some medications, particularly if inhaled, might influence VOC profile; this needs to be considered during future studies. Finally, the cohort of CF patients with *P. aeruginosa* infection in this initial proof-of-concept study comprised adult patients capable of expectorating sputum and chronically infected with *P. aeruginosa*. For a novel diagnostic screening test to be valuable, any signal would need to be sufficiently sensitive to discriminate between noninfected patients and those with early infection, probably with low bacterial numbers.

In summary, we confirm that by combining a series of measured VOC, CF patients with and without chronic *P. aeruginosa* infection can be differentiated on a group basis. The test is not sufficiently sensitive to be used on an individual case basis and significant improvements are probably needed before this can be applied to the population most in need, young patients with early infection.

@ERSpublications

Detecting *P. aeruginosa* infection is problematic; breath analysis shows promise but requires optimisation [1] http://ow.ly/WE1H2

Rishi Pabary¹,², Juzheng Huang³, Sacheen Kumar³, Eric W.F.W. Alton¹, Andrew Bush¹,², George B. Hanna³ and Jane C. Davies¹,²
¹National Heart and Lung Institute, Imperial College, London, UK. ²Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK. ³Dept of Surgery and Cancer, St Mary’s Hospital, London, UK.

Correspondence: Rishi Pabary, National Heart and Lung Institute, Emmanuel Kaye Building, 1b Manresa Road, London, SW3 6LR, UK. E-mail: r.pabary11@imperial.ac.uk

Received: April 19 2015 | Accepted after revision: Dec 06 2015

Support statement: This project was funded by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, UK. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, The National Institute for Health Research or the Department of Health.

Conflict of interest: None declared.

References


